Navigation Links
Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
Date:8/25/2009

WALTHAM, Mass., Aug. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade. Through 2013, the market will decrease by 1.4 percent annually and thereafter the annual decline will slow to 1 percent through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Hypertension finds that the major contributor to market decline will be the increasing generic availability of antihypertensive agents. By 2018, Diovan alone will lose more than $1 billion in sales, owing to generic erosion of the agent which will begin in 2010 in the U.S., in 2011 in Europe and in 2013 in Japan. Additionally, agents from drug classes that are typically used in first-, second-, and third-line therapy -- such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRAs), calcium-channel blockers (CCBs), and diuretics -- will all be subject to generic competition.

The report also finds that near-term opportunity in the hypertension market -- which is saturated with effective, well-established treatments -- lies in the development of therapies that offer greater convenience. Fixed-dose combinations such as CCB/renin-angiotensin-aldosterone system (RAAS) inhibitors and CCB/RAAS/diuretics will capitalize on this opportunity. By 2012, three fixed-dose combinations -- Novartis's Exforge HCT, Daiichi Sankyo's olmesartan/amlodipine/HCT, and Novartis's aliskiren/amlodipine/HCT -- will each be available in the world's major markets. While these agents will offer considerable improvements in convenience over currently available fixed-dose combinations, interviewed experts ex
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
2. Presentation of Phase IIa Results for Cytos Biotechnologys Hypertension Vaccine at the American Heart Association Scientific Sessions 2007
3. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
4. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
5. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
6. Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
7. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
8. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
9. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
10. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
11. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  The 12th ... officially kicks off September 29 at the John ... over Boston for a weeklong ... Cold Chain Global Forum is designed to cover the ... the modern cold chain, all temperature range products, GDP ...
(Date:9/29/2014)... 29, 2014  Perrigo Company plc (NYSE: ... has transferred a portfolio of preclinical research assets, ... of Elan Corporation plc, to drug discovery and ... agreement, Perrigo will receive an upfront payment in ... on any future sales derived from the portfolio. ...
(Date:9/29/2014)... , Sept. 29, 2014  Xcenda, the strategic ... global pharmaceutical sourcing and distribution service companies, recently ... consumption. This research was analyzed in an economic ... associated with an increase in life years and ... at population-level coffee consumption across the ...
(Date:9/29/2014)... 29, 2014 Westbridge Agricultural Products ... EC, a highly effective new tool for organic ... broad spectrum contact herbicide for post-emergent, non-selective weed ... non-food crops. The formulation is an emulsifiable concentrate ... Review Institute (OMRI) for use in organic food ...
Breaking Biology Technology:12th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... 29, 2012 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... to sell, subject to customary closing conditions, $40 million of ... to purchase shares of its common stock (and the shares ... of the Series 15 Convertible Preferred Stock and exercise and ...
... and TARRYTOWN, New York, May 26, 2012 ... SNY ) and Regeneron Pharmaceuticals, Inc. (NASDAQ: ... a Phase 2 trial of SAR236553/REGN727 (Study 1003, ... SAR236553/REGN727 is a subcutaneously administered, fully-human antibody targeting ...
... known that a diet high in fat and extremely low ... But how the diet worked, and why, was a mysteryso ... called it "Epilepsy,s Big, Fat Miracle." Now, researchers ... an answer, linking resistance to seizures to a protein that ...
Cached Biology Technology:Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 2Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 3Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 4Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 5Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 2Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 3Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 4Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 5Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 7Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 8Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 9Reverse engineering epilepsy's 'miracle' diet 2Reverse engineering epilepsy's 'miracle' diet 3
(Date:9/29/2014)... DETROIT In order to support the world,s ... chemicals, polymers and more, new and more efficient ... team of researchers, including several from Wayne State ... of a new grant from the National Science ... Guided Design of Multicomponent Materials for Electrocatalytic Cascade ...
(Date:9/29/2014)... Scientists at Washington State University have concluded ... Smith apples may help prevent disorders associated ... first to assess these compounds in apple cultivars ... print edition of the journal Food Chemistry ... a good source of these nondigestible compounds but ...
(Date:9/29/2014)... Santos has presented Dr. Cristin Samper, president and ... prestigious Order of San Carlos. , The Order ... and military officers who have made outstanding contributions ... international relations. , An international authority on conservation ... to the Colombian Residence in New York to ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2An apple a day could keep obesity away 2
... Interventional Radiology hailed the Sept. 11 decision by ... has oversight of the 24 recognized medical specialty ... for a new Dual Primary Certificate in Interventional ... and its member boards confirmed the benefit to ...
... JEJU, REPUBLIC OF KOREA (September 12, 2012) A ... biologically diverse place on earth, according to the Wildlife ... list of species found there. The announcement was ... gathering of conservationists meeting through Sept. 13 in Jeju, ...
... a man with apparent battle wounds and curvature of the ... the University of Leicester. The University of Leicester has ... King Richard III with Leicester City Council, in association with ... third week, has yielded dramatic findings of human remains which ...
Cached Biology News:Society of Interventional Radiology hails affirmation of specialty's role in patient care 2Society of Interventional Radiology hails affirmation of specialty's role in patient care 3Society of Interventional Radiology hails affirmation of specialty's role in patient care 4Amazing diversity documented in national park 2King Richard III search in new phase after 'discovery has potential to rewrite history' 2King Richard III search in new phase after 'discovery has potential to rewrite history' 3King Richard III search in new phase after 'discovery has potential to rewrite history' 4King Richard III search in new phase after 'discovery has potential to rewrite history' 5King Richard III search in new phase after 'discovery has potential to rewrite history' 6King Richard III search in new phase after 'discovery has potential to rewrite history' 7King Richard III search in new phase after 'discovery has potential to rewrite history' 8King Richard III search in new phase after 'discovery has potential to rewrite history' 9
... PolarScreen Progesterone Receptor (PR) Competitor ... or screening novel progesterone receptor binding ... homogenous assay utilizes a fusion of ... domain of human progesterone receptor [PR-LBD(GST)] ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential Neurological liabilities of compound...
... form from a hematopoietic stem cells called ... the bone surface and lowering the surrounding ... 4.5. The bone mineral is then solubilized ... function is controlled primarily by Macrophage Colony-Stimulating ...
Biology Products: